BioSpace News Archive

Sage Therapeutics, Inc., a biopharmaceutical company leading the way to create a world with better brain health, announced that it will host a live webcast on Monday, August 7, 2023 at 8:00 a.m. ET to provide a business update.

Basilea Pharmaceutica Ltd, Allschwil, a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced that it has submitted a New Drug Application to the US Food and Drug Administration.

Sosei Group Corporation provides an update on operational activities and reports its consolidated results for the second quarter and first half ended 30 June 2023.

Duchenne Muscular Dystrophy (DMD) patients showed signs of disease progress slowing down, after oral consumption of Neu REFIX ß-glucan for 45 days along with routine medications.

Zomedica Corp., a veterinary health company offering diagnostic and therapeutic products for companion animals, will host a conference call and audio-only webcast on Thursday, August 10, 2023 at 4:30 p.m. ET to discuss the Company’s operational and financial highlights for its second quarter ending June 30, 2023.

Amneal Pharmaceuticals, Inc. announced its results for the second quarter ended June 30, 2023.

Biovica International (STO:BIOVIC-B) (STO:BIOVIC.B) (FRA:9II) The shareholders of Biovica International AB, are hereby invited to the annual general meeting to be held on Tuesday 5 September 2023, at 10.00 CET in Conference Hubben’s premises on Dag Hammarskjolds Vag 38 in Uppsala.

Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that Chief Executive Officer Dr. Matt Coffey will participate in a fireside chat at Canaccord Genuity’s 43rd Annual Growth Conference, which is taking place August 7-10, 2023 at the InterContinental Boston in Boston, MA.

Newron Pharmaceuticals S.p.A. today announced its financial results and operational highlights for the half year ended June 30, 2023, and provided an update on its R&D and business activities.

Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading microbiome therapeutics company, today announced that on July 31, 2023, the Compensation and Talent Committee of Seres’ board of directors granted inducement equity grants covering an aggregate of 1950 shares of its common stock to one new employee.